Description

Cagrilintide is a well-known clinical drug in the peptide research field due to trials conducted alongside semaglutide, under the name CagriSema, for obesity and type 2 diabetes. The conjugated fatty acid long-acting amylin analogue has been developed to eliminate the problem of amylin aggregation and instability and is still relevant for research on appetite, glucose and weight control.

It comes as lyophilized powder in 5 mg vials with ≥98% purity (verified by HPLC). Appropriate for the studies of amylin receptor biochemistry, satiety, postprandial glucose metabolism, and GLP-1 agonists. Store at -20°C and keep refrigerated under appropriate laboratory conditions. For research use only.

Product Features:

Contains 5 mg lyophilised powder per vial
Purity: ≥98% as measured by HPLC
CAS Number: 2381272-85-9
Long-acting amylin analogue by virtue of fatty acid conjugation that extends the half-life
Has undergone clinical testing as a constituent of CagriSema drug mixture
Store at −20°C before reconstitution; refrigerate after